Bessemer Group Inc. Reduces Stock Position in Icon Plc $ICLR

Bessemer Group Inc. lowered its holdings in shares of Icon Plc (NASDAQ:ICLR) by 97.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 385 shares of the medical research company’s stock after selling 15,253 shares during the quarter. Bessemer Group Inc.’s holdings in Icon were worth $56,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ICLR. SVB Wealth LLC purchased a new stake in shares of Icon during the first quarter valued at $28,000. Ameritas Advisory Services LLC purchased a new stake in Icon in the 2nd quarter valued at about $48,000. LRI Investments LLC purchased a new stake in Icon in the 2nd quarter valued at about $49,000. Blue Trust Inc. boosted its position in Icon by 44.0% in the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after buying an additional 120 shares during the period. Finally, Greykasell Wealth Strategies Inc. purchased a new stake in Icon in the 1st quarter valued at about $69,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Trading Up 0.5%

Shares of NASDAQ ICLR opened at $163.70 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The stock has a market capitalization of $13.22 billion, a P/E ratio of 22.15, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23. Icon Plc has a 1-year low of $125.10 and a 1-year high of $231.89. The business has a fifty day moving average price of $177.72 and a 200 day moving average price of $159.99.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $3.31 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.03. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business posted $3.35 EPS. Equities research analysts expect that Icon Plc will post 13.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Leerink Partners set a $220.00 price target on Icon in a report on Thursday, October 23rd. Citigroup reiterated a “neutral” rating and issued a $200.00 target price (down from $225.00) on shares of Icon in a report on Thursday, August 21st. Mizuho upped their target price on Icon from $173.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Rothschild Redb upgraded Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, Evercore ISI upped their price objective on shares of Icon from $170.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $207.14.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.